NCT06365853 2025-12-18A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionAbbViePhase 2 Recruiting100 enrolled